No bill #: legislation to modernize CLIA
H.R.2369 - VALID Act of 2023
FDA Proposed Rulemaking on LDTs
S.2140: Patent Eligibility Restoration Act of 2023
Duration: February 1, 2019
to
present
General Issues: Medical/Disease Research/Clinical Labs , Copyright/Patent/Trademark , Health Issues , Consumer Issues/Safety/Protection , Medicare/Medicaid
Spending: about $937,500 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2019: U.S. Senate, House of Representatives, Office of Management & Budget (OMB), Health & Human Services - Dept of (HHS), Centers For Disease Control & Prevention (CDC), Federal Trade Commission (FTC), Government Accountability Office (GAO), Office of Science & Technology Policy (OSTP), Centers For Medicare and Medicaid Services (CMS), Natl Institutes of Health (NIH), Food & Drug Administration (FDA)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Jennifer Leib
Fellow, Senate Committee on Health, Education, Labor, and Pensions
Legislative Fellow, Committee on Health, Education, Labor, and Pensions
Fellow, Senate Health, Education, Labor and Pensions
Fellow, Senate Committee on Health, Education, Labor and Pensions
Megan Anderson Brooks
n/a
Jay Qiu
n/a
Lindsey Trischler
n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, iPolicy Solutions lobbied for Association for Molecular Pathology , earning $70,500. The report was filed on April 15.
Original Filing: 301549456.xml
Lobbying Issues
No bill #: legislation to modernize CLIA
H.R.2369 - VALID Act of 2023
FDA Proposed Rulemaking on LDTs
Agencies Lobbied
U.S. Senate U.S. House of Representatives Office of Management & Budget (OMB)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
S.2140: Patent Eligibility Restoration Act of 2023
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2023
In Q4, iPolicy Solutions lobbied for Association for Molecular Pathology , earning $62,000. The report was filed on Feb. 2.
Original Filing: 301542773.xml
Lobbying Issues
No bill #: legislation to modernize CLIA
H.R.2369 - VALID Act of 2023
FDA Proposed Rulemaking on LDTs
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
S.2140: Patent Eligibility Restoration Act of 2023
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2023
In Q3, iPolicy Solutions lobbied for Association for Molecular Pathology , earning $45,000. The report was filed on Oct. 16, 2023.
Original Filing: 301501412.xml
Lobbying Issues
No bill #: Verified Innovative Testing in American Laboratories Act
H.R.2369 - VALID Act of 2023
FDA Proposed Rulemaking on LDTs
Agencies Lobbied
U.S. Senate U.S. House of Representatives Office of Management & Budget (OMB)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
No bill #: Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization
Workforce shortages
National Biodefense Science Board Recommendations
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
S.2140: Patent Eligibility Restoration Act of 2023
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2023
In Q2, iPolicy Solutions lobbied for Association for Molecular Pathology , earning $58,000. The report was filed on July 10, 2023.
Original Filing: 301474053.xml
Lobbying Issues
No bill #: Verified Innovative Testing in American Laboratories Act
H.R.2369 - VALID Act of 2023
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
No bill #: Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization
Workforce shortages
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S.2140: Patent Eligibility Restoration Act of 2023
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2023
In Q1, iPolicy Solutions lobbied for Association for Molecular Pathology , earning $45,000. The report was filed on April 17, 2023.
Original Filing: 301452509.xml
Lobbying Issues
No bill #: Verified Innovative Testing in American Laboratories Act
H.R.2369 - VALID Act of 2023
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
No bill #: Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization
Workforce shortages
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2022
In Q4, iPolicy Solutions lobbied for Association for Molecular Pathology , earning $42,000. The report was filed on Jan. 3, 2023.
Original Filing: 301424719.xml
Lobbying Issues
HR 4128/S 2209 Verifying Accurate Leading-Edge IVCT Development (VALID) Act Coverage
S 1666, Verified Innovative Testing in American Laboratories (VITAL) Act
Laboratory testing for Mpox
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
S.4734 Patent Eligibility Restoration Act
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
S.3799, PREVENT Pandemics Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Agencies Lobbied
Federal Trade Commission (FTC)
Type of Issue
Consumer Issues/Safety/Protection
3rd Quarter, 2022
In Q3, iPolicy Solutions lobbied for Association for Molecular Pathology , earning $42,000. The report was filed on Oct. 17, 2022.
Original Filing: 301406003.xml
Lobbying Issues
HR 4128/S 2209 Verifying Accurate Leading-Edge IVCT Development (VALID) Act Coverage
S 1666, Verified Innovative Testing in American Laboratories (VITAL) Act
S.4348 - FDASLA Act of 2022
Agencies Lobbied
U.S. Senate U.S. House of Representatives Government Accountability Office (GAO)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
S.4734 Patent Eligibility Restoration Act
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
S.3799, PREVENT Pandemics Act
Pandemic response and supply chain issues
Laboratory workforce
Agencies Lobbied
U.S. Senate Office of Science & Technology Policy (OSTP) Centers For Medicare and Medicaid Services (CMS)
2nd Quarter, 2022
In Q2, iPolicy Solutions lobbied for Association for Molecular Pathology , earning $63,000. The report was filed on July 19, 2022.
Original Filing: 301384919.xml
Lobbying Issues
HR 4128/S 2209 Verifying Accurate Leading-Edge IVCT Development (VALID) Act Coverage
S 1666, Verified Innovative Testing in American Laboratories (VITAL) Act
S.4348 - FDASLA Act of 2022
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
U.S. Patent Act Sec. 101 Reforms
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
S.3799, PREVENT Pandemics Act
Pandemic response and supply chain issues
Agencies Lobbied
U.S. Senate Office of Science & Technology Policy (OSTP)
1st Quarter, 2022
In Q1, iPolicy Solutions lobbied for Association for Molecular Pathology , earning $42,000. The report was filed on April 20, 2022.
Original Filing: 301365672.xml
Lobbying Issues
HR 4128/S 2209 Verifying Accurate Leading-Edge IVCT Development (VALID) Act Coverage
S 1666, Verified Innovative Testing in American Laboratories (VITAL) Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
U.S. Patent Act Sec. 101 Reforms
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
S.3799, PREVENT Pandemics Act
Pandemic response and supply chain issues
Agencies Lobbied
U.S. Senate Office of Science & Technology Policy (OSTP)
4th Quarter, 2021
In Q4, iPolicy Solutions lobbied for Association for Molecular Pathology , earning $42,000. The report was filed on Jan. 19, 2022.
Original Filing: 301328667.xml
Lobbying Issues
HR 4128/S 2209 Verifying Accurate Leading-Edge IVCT Development (VALID) Act Coverage
S 1666, Verified Innovative Testing in American Laboratories (VITAL) Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
U.S. Patent Act Sec. 101 Reforms
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2021
In Q3, iPolicy Solutions lobbied for Association for Molecular Pathology , earning $42,000. The report was filed on Oct. 20, 2021.
Original Filing: 301308027.xml
Lobbying Issues
HR 4128/S 2209 Verifying Accurate Leading-Edge IVCT Development (VALID) Act Coverage
S 1666, Verified Innovative Testing in American Laboratories (VITAL) Act
NIH/FDA Request for Information on tools for next generation sequencing
Agencies Lobbied
U.S. Senate U.S. House of Representatives Natl Institutes of Health (NIH) Food & Drug Administration (FDA)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
U.S. Patent Act Sec. 101 Reforms
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2021
In Q2, iPolicy Solutions lobbied for Association for Molecular Pathology , earning $42,000. The report was filed on July 16, 2021.
Original Filing: 301277441.xml
Lobbying Issues
HR 4128/S 2209 Verifying Accurate Leading-Edge IVCT Development (VALID) Act Coverage
S 1666, Verified Innovative Testing in American Laboratories (VITAL) Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
H.R.1946 - To amend title XVIII of the Social Security Act to provide for Medicare coverage of multi-cancer early detection screening tests.
H.R.4110 - Reducing Hereditary Cancer Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
U.S. Patent Act Sec. 101 Reforms
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2021
In Q1, iPolicy Solutions lobbied for Association for Molecular Pathology , earning $42,000. The report was filed on April 15, 2021.
Original Filing: 301253733.xml
Lobbying Issues
No bill number, Verifying Accurate Leading-Edge IVCT Development (VALID) Act Coverage
No bill number, Verified Innovative Testing in American Laboratories (VITAL) Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
S.236 - Tracking COVID-19 Variants Act
H.R.1946 - To amend title XVIII of the Social Security Act to provide for Medicare coverage of multi-cancer early detection screening tests.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC)
Lobbying Issues
U.S. Patent Act Sec. 101 Reforms
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2020
In Q4, iPolicy Solutions lobbied for Association for Molecular Pathology , earning $37,500. The report was filed on Jan. 19, 2021.
Original Filing: 301234351.xml
Lobbying Issues
H.R. 6102/S. 3404, Verifying Accurate Leading-Edge IVCT Development (VALID) Act Coverage
S.3512, Verified Innovative Testing in American Laboratories (VITAL) Act
Laboratory test supply shortages
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
HR4393, Advancing Access to Precision Medicine Act
H.R. 6201, Families First Coronavirus Response Act
H.R. 748 Coronavirus Aid, Relief, and Economic Security Act (CARES) Act
H.R. 6800, The Health and Economic Recovery Omnibus Emergency Solutions Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
U.S. Patent Act Sec. 101 Reforms
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2020
In Q3, iPolicy Solutions lobbied for Association for Molecular Pathology , earning $37,500. The report was filed on Oct. 20, 2020.
Original Filing: 301217811.xml
Lobbying Issues
H.R. 6102/S. 3404, Verifying Accurate Leading-Edge IVCT Development (VALID) Act Coverage
S.3512, Verified Innovative Testing in American Laboratories (VITAL) Act
Laboratory test supply shortages
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
HR4393, Advancing Access to Precision Medicine Act
H.R. 6201, Families First Coronavirus Response Act
H.R. 748 Coronavirus Aid, Relief, and Economic Security Act (CARES) Act
H.R. 6800, The Health and Economic Recovery Omnibus Emergency Solutions Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2020
In Q2, iPolicy Solutions lobbied for Association for Molecular Pathology , earning $37,500. The report was filed on July 20, 2020.
Original Filing: 301194786.xml
Lobbying Issues
H.R. 6102/S. 3404, Verifying Accurate Leading-Edge IVCT Development (VALID) Act Coverage
S.3512, Verified Innovative Testing in American Laboratories (VITAL) Act
Laboratory test supply shortages
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
HR4393, Advancing Access to Precision Medicine Act
H.R. 6201, Families First Coronavirus Response Act
H.R. 748 Coronavirus Aid, Relief, and Economic Security Act (CARES) Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2020
In Q1, iPolicy Solutions lobbied for Association for Molecular Pathology , earning $37,500. The report was filed on April 17, 2020.
Original Filing: 301170065.xml
Lobbying Issues
H.R. 6102/S. 3404, Verifying Accurate Leading-Edge IVCT Development (VALID) Act Coverage
S.3512, Verified Innovative Testing in American Laboratories (VITAL) Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
HR4393, Advancing Access to Precision Medicine Act
H.R. 6201, Families First Coronavirus Response Act
H.R. 748 Coronavirus Aid, Relief, and Economic Security Act (CARES) Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2019
In Q4, iPolicy Solutions lobbied for Association for Molecular Pathology , earning $40,000. The report was filed on Jan. 15, 2020.
Original Filing: 301106614.xml
Lobbying Issues
No bill #, Verifying Accurate Leading-Edge IVCT Development (VALID) Act Coverage
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare coverage of next generation sequencing based tests for cancer
HR4393, Advancing Access to Precision Medicine Act
H.R.3584, Laboratory Access for Beneficiaries Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
No bill #, reform Sec. 101 of the Patent Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2019
In Q3, iPolicy Solutions lobbied for Association for Molecular Pathology , earning $40,000. The report was filed on Oct. 11, 2019.
Original Filing: 301064817.xml
Lobbying Issues
No bill #, Verifying Accurate Leading-Edge IVCT Development (VALID) Act Coverage
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare coverage of next generation sequencing based tests for cancer
HR4393, Advancing Access to Precision Medicine Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
No bill #, reform Sec. 101 of the Patent Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2019
In Q2, iPolicy Solutions lobbied for Association for Molecular Pathology , earning $40,000. The report was filed on July 21, 2019.
Original Filing: 301053467.xml
Lobbying Issues
No bill #, Verifying Accurate Leading-Edge IVCT Development (VALID) Act Coverage
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare coverage of next generation sequencing based tests for cancer
No bill #, Advancing Access to Precision Medicine Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
No bill #, reform Sec. 101 of the Patent Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2019
In Q1, iPolicy Solutions lobbied for Association for Molecular Pathology , earning $30,000. The report was filed on April 8, 2019.
Original Filing: 301023311.xml
Lobbying Issues
No bill #, Verifying Accurate Leading-Edge IVCT Development (VALID) Act Coverage
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare coverage of next generation sequencing based tests for cancer
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
1st Quarter, 2019
iPolicy Solutions filed a lobbying registration on March 4, 2019 to represent Association for Molecular Pathology, effective Feb. 1, 2019.
Original Filing: 301021081.xml
Issue(s) they said they’d lobby about: No bill #, Verifying Accurate Leading-Edge IVCT Development (VALID) Act
Coverage and reimbursement for molecular diagnostics .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate